3 results match your criteria: "Department of Surgical Oncology Gifu University Graduate School of Medicine Gifu Japan.[Affiliation]"
Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm phase II study (NAC-GA trial).
Ann Gastroenterol Surg
November 2023
Department of Cancer Immunology Wakayama Medical University Wakayama Japan.
Article Synopsis
- Nab-paclitaxel plus gemcitabine (GnP-NAT) was tested as a neoadjuvant therapy in a phase II trial involving 61 patients with borderline resectable pancreatic cancer, focusing on overall survival and disease progression.
- The results showed a median overall survival of 25.2 months and a significant resection rate, although 73.8% of patients experienced serious side effects (grade 3/4 events).
- The study suggests GnP-NAT is a promising treatment, but highlights caution for patients with previous pulmonary issues and emphasizes the need for further research into its safety and effectiveness.
Aim: Gastric cancer is the second leading cause of cancer death worldwide. Surgery is the mainstay treatment for gastric cancer. There are no prediction models that examine the severity of postoperative morbidity.
View Article and Find Full Text PDFBackground: Quality of life (QoL) is a key component in decision-making for surgical palliation, but QoL data in association with surgical palliation in advanced gastric cancer are scarce. The aim of this multicentre observational study was to examine the impact of surgical palliation on QoL in advanced gastric cancer.
Methods: The study included patients with gastric outlet obstruction caused by incurable advanced primary gastric cancer who had no oral intake or liquid intake only.